{"DataElement":{"publicId":"61281","version":"5","preferredName":"Contraception Agreement Reproduction Ind","preferredDefinition":"the indicator that asks whether patients receiving therapy or interventions have agreed to prevent pregnancy until the end of therapy or interventions.","longName":"CONTRACEPT_AGR_IND","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2014053","version":"1","preferredName":"Contraception Agreement","preferredDefinition":"the patient's agreement to use effective contraception during protocol treatment.","longName":"CONTRACEPTION_AGR","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2725194","version":"1","preferredName":"Contraception","preferredDefinition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.","longName":"C37932","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Contraception","conceptCode":"C37932","definition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"448E87D9-8E4A-47E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-25","modifiedBy":"ONEDATA","dateModified":"2008-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2520617","version":"1","preferredName":"Agreement","preferredDefinition":"1. The act of agreeing. 2. Harmony of opinion; accord. (from American Heritage Dictionary)","longName":"C25369","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agreement","conceptCode":"C25369","definition":"The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1DFE6E80-0641-12A3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-21","endDate":null,"createdBy":"AYANLOWA","dateCreated":"2006-09-21","modifiedBy":"ONEDATA","dateModified":"2006-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008542","version":"1","preferredName":"Reproduction","preferredDefinition":"the patient's ability to conceive or nurse offspring and/or their current reproductive status.","longName":"REPRODUCTION","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227DAE6-EC15-4A7D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B318870A-C908-3702-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-31","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018560","version":"2","preferredName":"Reproduction Ind","preferredDefinition":"a yes/no indicator, related to reproduction, that may contain other related answers (e.g., Not assessed).","longName":"REPRODUCTION_IND","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE26FF2D-B560-5D95-E053-4EBD850A6133","beginDate":"2002-08-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE26FF2D-B56A-5D95-E053-4EBD850A6133","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE26FF2D-B556-5D95-E053-4EBD850A6133","beginDate":"2002-08-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","deletedIndicator":"No"},{"value":"Not Applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"2970452","version":"1","preferredName":"Not Applicable","longName":"2970452","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AF0EB2A-C470-9AE1-E040-BB89AD435D16","latestVersionIndicator":"Yes","beginDate":"2009-12-17","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-12-17","modifiedBy":"ZHANGWE","dateModified":"2021-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE26FF2D-B57E-5D95-E053-4EBD850A6133","beginDate":"2009-12-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","deletedIndicator":"No"},{"value":"NA patient is not of reproductive potential","valueDescription":"N/A, patient is not of reproductive potential","ValueMeaning":{"publicId":"2565619","version":"1","preferredName":"N/A, patient is not of reproductive potential","longName":"2565619","preferredDefinition":"N/A, patient is not of reproductive potential","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CD60-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-03","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-03","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE26FF2D-B588-5D95-E053-4EBD850A6133","beginDate":"2012-05-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","deletedIndicator":"No"},{"value":"NA patient is not sexually active","valueDescription":"NA patient is not sexually active","ValueMeaning":{"publicId":"7412132","version":"1","preferredName":"NA patient is not sexually active","longName":"7412132","preferredDefinition":"NA patient is not sexually active","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE599C94-ADC5-231B-E053-4EBD850A9E55","latestVersionIndicator":"Yes","beginDate":"2020-09-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-09-02","modifiedBy":"ONEDATA","dateModified":"2020-09-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE26FF2D-B592-5D95-E053-4EBD850A6133","beginDate":"2020-09-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008542","version":"1","preferredName":"Reproduction","preferredDefinition":"the patient's ability to conceive or nurse offspring and/or their current reproductive status.","longName":"REPRODUCTION","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227DAE6-EC15-4A7D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2320047","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FC6EF0D8-521A-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE26FF2D-B541-5D95-E053-4EBD850A6133","latestVersionIndicator":"Yes","beginDate":"2021-03-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-03-22","modifiedBy":"CAMPBELB","dateModified":"2021-03-22","changeDescription":"created for COG ADVL0212.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811959","version":"1","longName":"Patient Char.","context":"CTEP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000287","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"4104909","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"10000288","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"4104890","version":"1","longName":"GOG-0229L","context":"NRG"},{"publicId":"4104881","version":"1","longName":"GOG-0227G","context":"NRG"},{"publicId":"4104893","version":"1","longName":"GOG-0230D","context":"NRG"},{"publicId":"4104889","version":"1","longName":"GOG-0229K","context":"NRG"},{"publicId":"4104883","version":"1","longName":"GOG-0240","context":"NRG"},{"publicId":"4171062","version":"1","longName":"RTOG-1005","context":"NRG"},{"publicId":"4104994","version":"1","longName":"RTOG-1201","context":"NRG"},{"publicId":"4104991","version":"1","longName":"GOG-0275","context":"NRG"},{"publicId":"4104916","version":"1","longName":"GOG-0257","context":"NRG"},{"publicId":"10000500","version":"1","longName":"GOG-0257","context":"NRG"},{"publicId":"10000499","version":"1","longName":"GOG-0257","context":"NRG"},{"publicId":"4104886","version":"1","longName":"GOG-0265","context":"NRG"},{"publicId":"4104917","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"10000174","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"10000175","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"4104901","version":"1","longName":"GOG-0286B","context":"NRG"}]},{"publicId":"4254096","version":"1","longName":"Protocol Phase","context":"PBTC","ClassificationSchemeItems":[{"publicId":"10000103","version":"1","longName":"Phase I","context":"PBTC"},{"publicId":"4254119","version":"1","longName":"PBTC-042","context":"PBTC"}]}],"AlternateNames":[{"name":"PtAgrEffContrcep","type":"COG GDE Short Name","context":"CTEP"},{"name":"CONTRACEPT_AGR_IND3","type":"COG Form Element","context":"CTEP"},{"name":"CONTRACEPT_AGR_IND_COG","type":"COG Form Element","context":"CTEP"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"CRF Text18","type":"Alternate Question Text","description":"If male, does patient agree to use a latex condom during sexual contact with a female of child bearing potential, even if they have had a successful vasectomy?","url":null,"context":"CTEP"},{"name":"GOG_CRF Text","type":"Alternate Question Text","description":"If patient is of childbearing potential, is she practicing an effective method of birth control?","url":null,"context":"NRG"},{"name":"NRG_Text","type":"Alternate Question Text","description":"If the patient is of reproductive age and has not undergone a hysterectomy, has she agreed to use an effective contraceptive method for the duration of this study?","url":null,"context":"CTEP"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study treatment?","url":null,"context":"CTEP"},{"name":"CRF Text20","type":"Alternate Question Text","description":"Pregnancy or women of child bearing potential and men who are sexually active  and not willing/able to use medically acceptable forms of contraception","url":null,"context":"NRG"},{"name":"COG CRF TEXT 4","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the protocol therapy?","url":null,"context":"COG"},{"name":"Theradex Question","type":"Alternate Question Text","description":"Does male patient of fathering potential, agree to use a condom if partner is pregnant or breastfeeding?","url":null,"context":"Theradex"},{"name":"COG CRF TEXT 5","type":"Alternate Question Text","description":"Has the patient agreed to use an effective contraceptive method for the duration of the protocol therapy and for at least 1 month after treatment?","url":null,"context":"CTEP"},{"name":"CRF Text 21","type":"Alternate Question Text","description":"Patient treated or enrolled on this protocol must agree to use 2 methods of adequate contraception for the duration of the study participation, and 4 month(s) after discontinuing therapy.","url":null,"context":"CTEP"},{"name":"COG CRF Text 7","type":"Alternate Question Text","description":"Has patient agreed to abstinence or to use forms of effective contraception for the duration of protocol treatment and for at least 1 month off therapy?","url":null,"context":"CTEP"},{"name":"COG CRF TEXT 6","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of their study participation and for 30 days after the last dose of chemotherapy?","url":null,"context":"CTEP"},{"name":"ALT 1","type":"Alternate Question Text","description":"Has the patient of childbearing or child fathering potential agreed to use adequate contraceptive measures during study treatment?","url":null,"context":"ECOG-ACRIN"},{"name":"CRF_Text_22","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study participation and for 5 months after the end of study treatment?","url":null,"context":"CTEP"},{"name":"COG CRF Text 23","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study participation and for a minimum of 2 months after the last dose of ch 14.18 (Dinutuximab)?","url":null,"context":"CTEP"},{"name":"COG CRF Text 9","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study treatment and 4 weeks after last treatment dose?","url":null,"context":"CTEP"},{"name":"COG CRF Text 8","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study treatment and 5 months after last treatment dose?","url":null,"context":"CTEP"},{"name":"COG CRF Text 24","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study participation and for a minimum of 2 months after the last dose of CDX-011?","url":null,"context":"CTEP"},{"name":"ABTC-1501 Alt Question","type":"Alternate Question Text","description":"Has patient agreed to use two methods of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment, and through 23 weeks for women or 31 weeks for men after the last dose of the study?","url":null,"context":"ABTC"},{"name":"COG CRF Text 25","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method during study and for 2 months after stopping study drug?","url":null,"context":"CTEP"},{"name":"COG CRF Text 26","type":"Alternate Question Text","description":"Has the patient agreed to use an effective contraceptive method for the duration of the protocol therapy and for at least 3 months after treatment is completed?","url":null,"context":"COG"},{"name":"CRF_Text 23","type":"Alternate Question Text","description":"Has female patients of childbearing potential and men receiving pembrolizumab who are sexually active with women of childbearing potential agreed to use an adequate method of contraception for the course of the study through 120 days after the last dose of pembrolizumab?","url":null,"context":"NRG"},{"name":"ABTC 1501","type":"Alternate Question Text","description":"Has patient agreed to use two methods of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment, and through at least 23 weeks for women or at least 32 weeks for men after the last dose of study drug?","url":null,"context":"ABTC"},{"name":"NRG C RF_Text27","type":"Alternate Question Text","description":"Has patient agreed to use two methods of study doctor approved birth control or abstain from heterosexual activity for the course of the study from Screening through 120 days after the last dose of study medication?","url":null,"context":"NRG"},{"name":"COG CRF Text 41","type":"Alternate Question Text","description":"Has patient, male or female, agreed to use an effective contraceptive method for the duration  of the study and for 4-months after the last dose of enasidenib?","url":null,"context":"COG"},{"name":"COG CRF TEXT 42","type":"Alternate Question Text","description":"Did the patient agreed to use an effective contraceptive during treatment and for at least 6 months after the last dose of gilteritinib?","url":null,"context":"COG"},{"name":"COG CRF Text 38","type":"Alternate Question Text","description":"Has male patient of reproductive potential agreed to use a condom and their female partner agreed to use one of the highly effective methods of contraception duration of their study participation and for at least 90 days after last dose of Nirogacestat?","url":null,"context":"COG"},{"name":"COG CRF Text 103","type":"Alternate Question Text","description":"Has the patient agreed to use an effective contraceptive method for the duration of  protocol therapy and for at least 12 weeks after stopping study therapy?","url":null,"context":"COG"},{"name":"COG CRF Text 91","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of their study participation?","url":null,"context":"COG"},{"name":"CRF Text 44","type":"Alternate Question Text","description":"Does she agree to use two methods of contraception (hormonal or barrier method of birth control; abstinence)?","url":null,"context":"NRG"},{"name":"COG CRF Text  001","type":"Alternate Question Text","description":"Has the patient agreed to use an effective contraceptive method for the duration of their study participation?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_1","type":"Alternate Question Text","description":"Does he agree to use adequate contraception prior to the study, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6?","url":null,"context":"NRG"},{"name":"CRF Text","type":"Alternate Question Text","description":"Contraception Agreed Ind","url":null,"context":"CTEP"},{"name":"Has patient agreed to use con","type":"Preferred Question Text","description":"Has patient agreed to use contraception during protocol?","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Is the patient willing to use contraceptive techniques during the length of lenalidomide maintenance therapy","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"If patient is of childbearing potential, has she agreed to use contraceptive measures during study therapy and for at least 6 months after completion of Bevacizumab therapy","url":null,"context":"CTEP"},{"name":"CRF Text10","type":"Alternate Question Text","description":"If the patient is of child bearing potential, has she agreed to use an accepted and effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time of signing the informed consent through the duration of being on study","url":null,"context":"CTEP"},{"name":"CRF Text7","type":"Alternate Question Text","description":"If patient has the capacity to become pregnant, has she agreed to use an accepted and effective non-hormonal method of contraception i.e., double barrier method (eg. condom plus diaphragm) from the time of signing the informed consent through six months after the last dose of study drug?","url":null,"context":"CTEP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Has the patient agreed to practice an effective form of contraception during the study and for at least three months after receiving the final treatment of Brivanib?","url":null,"context":"CTEP"},{"name":"CRF Text6","type":"Alternate Question Text","description":"If patient has the capacity to become pregnant, has she agreed to use adequate contraception (two barrier methods of birth control) prior to study entry and for the duration of the study and up to three months after the final dose of BIBF1120?","url":null,"context":"CTEP"},{"name":"CRF Text9","type":"Alternate Question Text","description":"Is she willing to exercise an effective form of birth control during radiation therapy","url":null,"context":"CTEP"},{"name":"CRF TEXT 1","type":"Alternate Question Text","description":"If randomized to receive radiation therapy, did the woman agree to use contraception as defined in the protocol?","url":null,"context":"NRG"},{"name":"CRF_Text_25","type":"Alternate Question Text","description":"Does the patient agree to use adequate contraception when sexually active and to continue contraception for 6 months after study therapy?","url":null,"context":"CTEP"},{"name":"CRF_Text 26","type":"Alternate Question Text","description":"Does the patient and her sexual partner(s) agree to use adequate contraception when sexually active for the duration of the study and for 6 months after finishing study drug?","url":null,"context":"NRG"},{"name":"COG CRF Text 27","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study treatment and for at least 4 months after last treatment dose?","url":null,"context":"COG"},{"name":"COG CRF Text 28","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of their study participation and additional months after the last dose of study agent?","url":null,"context":"COG"},{"name":"NRG CRF_Text 28","type":"Alternate Question Text","description":"Has females of child-bearing potential and males agreed to use highly effective contraceptive precautions during the trial and up to 12 months following the last dose of study treatment?","url":null,"context":"NRG"},{"name":"COG CRF Text 29","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method (including abstinence) for the duration of study participation?","url":null,"context":"COG"},{"name":"CRF TEXT 29","type":"Alternate Question Text","description":"Does the patient agree to use a condom and another method of birth control during sexual contact with a female of child bearing potential, even men with a vasectomy, or use a condom if he has sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug?","url":null,"context":"NRG"},{"name":"CRF Text 30","type":"Alternate Question Text","description":"Do they agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after the last dose of bevacizumab and 6 months after the last dose of mFOLFOX6?","url":null,"context":"CTEP"},{"name":"MA39","type":"Alternate Question Text","description":"If a women of childbearing potential (WOCBP), patient has agreed to use an effective contraceptive method","url":null,"context":"CCTG"},{"name":"ABTC 1603","type":"Alternate Question Text","description":"Does the female patient of childbearing potential agree to use adequate contraception prior to study entry, for the duration of study treatment, and through at least 5 months after the last dose of study drug?","url":null,"context":"CTEP"},{"name":"COG CRF Text 102","type":"Alternate Question Text","description":"Has the male patient of reproductive potential agreed to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy?","url":null,"context":"COG"},{"name":"PBTC_Text10","type":"Alternate Question Text","description":"Has patient of childbearing or child fathering potential agreed to follow the protocol required pregnancy prevention practice?","url":null,"context":"PBTC"},{"name":"COG CRF Text 10","type":"Alternate Question Text","description":"Is the patient sexually active, of reproductive potential and have not agreed to use an effective contraceptive method for the duration of their study participation?","url":null,"context":"COG"},{"name":"COG CRF TEXT 31","type":"Alternate Question Text","description":"Has the male patient agreed to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy?","url":null,"context":"COG"},{"name":"COG CRF TEXT 30","type":"Alternate Question Text","description":"Has female patient agreed to either practice 2 medically accepted highly effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 5 months after the last dose of the study drug?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Does women of child-bearing potential and men agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for the 5 months (150 days) after the last dose of the study agent? If not woman of childbearing potential (check N/A)","url":null,"context":"NRG"},{"name":"COG CRF Text 100","type":"Alternate Question Text","description":"Has the patient agreed to use an effective contraceptive method for the duration of their study participation and for 6 months after the last dose of protocol-specified treatment?","url":null,"context":"COG"},{"name":"COG CRF TEXT 32","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study therapy and for two months after the last dose of dinutuximab?","url":null,"context":"COG"},{"name":"CRF Text8","type":"Alternate Question Text","description":"Has the patient agreed to practice an effective form of contraception during protocol therapy and for at least two months following completion of protocol therapy?","url":null,"context":"CTEP"},{"name":"CRF Text11","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study participation?","url":null,"context":"CTEP"},{"name":"CRF Text13","type":"Alternate Question Text","description":"Has the patient agreed to use an accepted method of contraception for the duration of the study?","url":null,"context":"CTEP"},{"name":"CRF Text12","type":"Alternate Question Text","description":"Patient of child-bearing potential is willing to employ adequate contraception","url":null,"context":"CTEP"},{"name":"CRF Text14","type":"Alternate Question Text","description":"Is the patient of childbearing potential and not practicing adequate contraception?","url":null,"context":"CTEP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Has patient and their partner agreed to use an effective contraceptive method for the duration of the study participation?","url":null,"context":"CTEP"},{"name":"COG CRF Text 33","type":"Alternate Question Text","description":"Has patient and their partner agreed to use adequate contraception while enrolled on this study?","url":null,"context":"COG"},{"name":"COG CRF TEXT 11","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study participation and for 12 months following completion of study therapy?","url":null,"context":"COG"},{"name":"COG CRF Text 34","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method?","url":null,"context":"COG"},{"name":"COG CRF Text 35","type":"Alternate Question Text","description":"Has the patient agreed to use an effective contraceptive method for the duration of the protocol therapy and for at least 12 weeks after stopping study therapy?","url":null,"context":"COG"},{"name":"CRF TEXT 37","type":"Alternate Question Text","description":"If randomized to Arm 2, is the patient or patient's partner willing to use barrier method of contraception for 12 months after receiving Toca 511 and 1 month after stopping Toca FC or until there is no evidence of the virus in the patient's blood, whichever is longer","url":null,"context":"NRG"},{"name":"COG CRF Text 101","type":"Alternate Question Text","description":"Has the patient agreed to use an effective contraceptive method for the duration of their study participation and for 4 months following discontinuation of study therapy?","url":null,"context":"COG"},{"name":"NRG CRF_Text 30","type":"Alternate Question Text","description":"Is the patient currently pregnant or breastfeeding or a Women or a Man who is sexually active and not willing/able to use medically acceptable forms of contraception?","url":null,"context":"NRG"},{"name":"NRG Alt Text 33","type":"Alternate Question Text","description":"If the patient is a woman of childbearing potential or a man who is sexually active, do they agree to use medically acceptable contraception?","url":null,"context":"CTEP"},{"name":"NRG_CRF Text 31","type":"Alternate Question Text","description":"Does women of childbearing potential and men who are sexually active agree to use medically acceptable forms of contraception for up to 5 months from last study treatment?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text 29","type":"Alternate Question Text","description":"If randomized to Arm 2, is the patient or their partner willing to use barrier method of contraception for 12 months after receiving Toca 511 and 1 month after stopping Toca FC or until there is no evidence of the virus in the patients blood, whichever is longer","url":null,"context":"NRG"},{"name":"CRF Text 38","type":"Alternate Question Text","description":"Has the patient agreed to use effective contraception from study entry, duration of protocol treatment and after the last administered injection of OBP-301 as mandated in the protocol?","url":null,"context":"NRG"},{"name":"Princess Margaret-1","type":"Alternate Question Text","description":"Has patient agreed to protocol-defined methods of contraception?","url":null,"context":"NCIP"},{"name":"COG CRF Text 36","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study participation and for 30 days after the last dose of chemotherapy?","url":null,"context":"COG"},{"name":"COG CRF TEXT 37","type":"Alternate Question Text","description":"Did patient agreed to use an effective contraceptive during treatment and for at least 4 months after the last dose of gilteritinib?","url":null,"context":"COG"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Women of childbearing potential and men must agree to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time the consent is signed, during the duration of study participation, and 4 months after discontinuation of protocol therapy. If not woman of childbearing potential (check N/A)","url":null,"context":"CTEP"},{"name":"AECC Text 1","type":"Alternate Question Text","description":"Prior to study entry and for the duration of the study, has patient agreed to use an effective contraceptive method? (N/A only if patient is not of childbearing potential)","url":null,"context":"AECC"},{"name":"CRF Text16","type":"Alternate Question Text","description":"Patient treated or enrolled on this protocol must agree to use adequate contraception for the duration of the study participation, and 4 month(s) after discontinuing therapy","url":null,"context":"CTEP"},{"name":"CRF TEXT 15","type":"Alternate Question Text","description":"Has the patient agreed to use an effective contraception method during protocol treatment and for at least 6 months following treatment?","url":null,"context":"CTEP"},{"name":"ABTC Question Text","type":"Alternate Question Text","description":"Has the patient (women of child bearing potential and men) agreed to use two birth control methods or abstinence prior to study entry and for the duration of study participation?","url":null,"context":"CTEP"},{"name":"CRF Text 19","type":"Alternate Question Text","description":"Women of childbearing potential and men must agree to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time the consent is signed, for the duration of study participation, and 4 months after discontinuation of protocol therapy.  If not a woman of childbearing potential (check N/A).","url":null,"context":"CTEP"},{"name":"CRF Text 18","type":"Alternate Question Text","description":"Did the patient agree to use an adequate contraceptive method during the study treatment period for at least 1 month after the last study treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study treatment and for 3 months after stopping treatment?","url":null,"context":"CTEP"},{"name":"NRG_Text_34","type":"Alternate Question Text","description":"Does the patient agree to use a highly effective contraception if having sex with a woman of childbearing potential or a woman who is pregnant while on study drug and for 2 weeks following the last dose of study drug.","url":null,"context":"NRG"},{"name":"COG CRF Text 92","type":"Alternate Question Text","description":"Has the patient agreed to use an effective contraceptive method for the duration of study treatment and for 90 days after the last dose of selinexor?","url":null,"context":"COG"},{"name":"NRG_Text_30","type":"Alternate Question Text","description":"If yes, Does she agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 5 months after the last dose of investigational drug?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_3","type":"Alternate Question Text","description":"Is she willing and able to use adequate contraception (hormonal and barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after the last dose of study agent?","url":null,"context":"NRG"},{"name":"NRG_Text_31","type":"Alternate Question Text","description":"Does she agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 5 months after the last dose of investigational drug?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_2","type":"Alternate Question Text","description":"Does she agree to use two forms of birth control (hormonal or barrier method of birth control; abstinence) or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 28 days after the last dose of ipatasertib and agreement to refrain from donating eggs during this same period?","url":null,"context":"NRG"},{"name":"COG CRF 43","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study participation and for 12 weeks after the last dose of IMGN632?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_33","type":"Alternate Question Text","description":"Does she agree to use two forms of birth control (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 6 months after completion of the study?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text_35","type":"Alternate Question Text","description":"Does she agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and for 1 month after the last dose of copanlisib and/or olaparib?","url":null,"context":"NRG"},{"name":"COG CRF Text 39","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of the study participation and for 12 weeks after the last dose of IMGN632 or 6 months after last dose of DAUNOrubicin and cytarabine liposome, whichever is longer?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_4","type":"Alternate Question Text","description":"Does she agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during study therapy and for 28 days following the last dose of study therapy?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text_1","type":"Alternate Question Text","description":"Does she agree to use two forms of birth control (hormonal or barrier method of birth control; abstinence) during the study and for 12 weeks after completing treatment?","url":null,"context":"NRG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Is the patient a woman of  childbearing  potential?","url":null,"context":"NRG"},{"name":"COG CRF Text 12","type":"Alternate Question Text","description":"Has patient, male or female, agreed to use an effective contraceptive method for the duration of the study and for 2-months after the last dose of enasidenib?","url":null,"context":"COG"},{"name":"NRG CRF Text 2","type":"Alternate Question Text","description":"Does she agree to use highly effective contraceptives during therapy?","url":null,"context":"NRG"},{"name":"COG CRF Text 13","type":"Alternate Question Text","description":"Has patient agreed to use an effective contraceptive method for the duration of their study participation and following therapy?","url":null,"context":"COG"},{"name":"NRG CRF Text 3","type":"Alternate Question Text","description":"Does he agree to use adequate contraception prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6?","url":null,"context":"NRG"},{"name":"NRG CRF Text 4","type":"Alternate Question Text","description":"Does the patient agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 6 months following the last dose?","url":null,"context":"NRG"},{"name":"NRG CRF Text 5","type":"Alternate Question Text","description":"Is the patient of childbearing potential?","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BE27271D-563D-7B13-E053-4EBD850A7C7B","latestVersionIndicator":"Yes","beginDate":"2021-03-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-03-22","modifiedBy":"TYRRELLM","dateModified":"2023-09-29","changeDescription":"In use on one or more approved CRFs.  ISO 11179 compliance.","administrativeNotes":"9.29.2023 Added AQT per request CADSR0002901_mmt\r\n7/21/23 removed special character from AQT_mmt\r\n2023.3.17 AQT added per ticket request CADSR0002164. ak 20223.1.9 AQT added per ticket request CADSR0001884. ak 2022.12.20 AQT added for ticket request CADSR0001812. ak  2022.11.15 AQT added for Ticket request CADSR0001687. ak 7/20/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"}}